Acquisition Expands Satellite Antenna Capability

Wednesday, June 17, 2020

Kratos Defense & Security (KTOS)

Acquisition Expands Satellite Antenna Capability

Kratos Defense & Security Solutions is a National Security technology provider with proprietary expertise in the area of unmanned aerial vehicles, electronics for missile defense systems, electronic warfare systems, satellite control and management systems and support services for emerging naval weapon systems. Commercial and state and local government revenues are about 25% of the total and comprise primarily of critical infrastructure monitoring and protection systems.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    ASC Signal Acquisition. Yesterday, Kratos announced the acquisition of ASC Signal for $35 million. ASC is a manufacturer of high-performance, highly engineered antenna systems for satellite communications, radar, electronic warfare, and high-frequency applications. While details of the business size were not provided, we would note the business was running at a $50 million revenue rate back in 2016. Notably, the Department of Justice required the sale of ASC in order for Communications and Power Industries to proceed with its proposed acquisition of General Dynamics SATCOM Technologies, Inc.

    Synergies and Expansion. The acquisition brings numerous synergies with Kratos’ existing core space business and expands Kratos’ industry-broadest offering of advanced products across the ground station segment. ASC antennas are used in a variety of mission-critical space applications, ranging from Telemetry, Tracking & Command to satellite communications and earth sensing and observation for military and…



    Click to get the full report.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Is Elon Musk’s “Battery Day” Losing its Charge?

Will Tesla’s Big Reveal Slash Electric Vehicle Prices?

Elon Musk said the forthcoming “Battery Day” would be “one of the most exciting days in Tesla’s history.” This was announced after Tesla’s Q1 2020 earnings report in late April. The Tesla CEO said the event might be a two-part special, with a webcast first, and an in-person event a few months later. They were scheduled to reveal their new advanced battery technology on May 18 (Battery Day), the coronavirus lockdown postponed the event. To date, it has not been rescheduled.

Tesla has been frustratingly quiet regarding the highly anticipated event, although rumors and leaks have been rampant. Most people expect Tesla to unveil a less expensive electric battery that will last one million miles, something not seen in the automotive industry before. Tesla is also rumored to avoid the use of costly cobalt in the company’s next-gen batteries.

Musk has estimated that current Tesla batteries last between 300  and 500 thousand miles (approx.. 1500 cycles). An average vehicle is expected to last, on average, 200 thousand miles. Jeff Dahn, a professor in the Department of Physics & Atmospheric Science and the department of chemistry at Dalhousie University, who joined Tesla in 2016 to conduct research, has said lithium-ion batteries, which are used to power electric vehicles, have the capability of lasting over 1 million miles.

Tesla, along with Dahn, filed a patent to use dioxazolones and nitrile sulfites as electrolyte additives. The outcome, the introduction of a new lithium-ion battery. The patent claims to provide new energy, efficiency, and longevity. The cathode structure would increase durability, creating a longer lifespan and result in more charging cycles and greater mileage.

In January of 2020, Tesla started production with CATL, a leading supplier for batteries in China. In February, a report from Reuters announced Tesla was “in talks” to use CATL’s lithium-ion phosphate batteries, which completely excludes the use of cobalt, which is the most expensive metal in EV batteries. In 2018, Elon Musk tweeted that Tesla uses 3% cobalt now, and they plan on being cobalt-free in their next-gen batteries.

As Tesla aims to improve affordability for their electric vehicles, the company is reaching for a price point below $100/kWh, a number industry experts have said would make them directly comparable, price-wise, to gas-powered vehicles. Today, electric vehicle batteries can be found no lower than $150/kWh.

Tesla recently announced plans for a new factory in Austin, Texas. They had previously announced plans for a “Cybertruck Gigafactory.” Musk has said that he hopes to have vehicles produced by the end of the year, an extremely aggressive and optimistic timeline.

In 2019, Tesla’s Model 3 was by far the best-selling electric vehicle, selling over 67,650. Tesla also held second place, with the Model X SUV, and took 3 out of the top 5 spots among EV makers. Just yesterday, Tesla announced a price cut on the company’s Model S and improved the range to 402 miles on a single charge, the first electric vehicle with such capabilities; a 20% increase when compared to the 2019 model.

 

U.S. Battery Electric Vehicle Sales in 2019, by Brand

The number of battery electric vehicles sold in the United States came to about 245,000 in 2019, with sales of Tesla models accounting for almost 80 percent of that figure. Second-ranked Chevrolet accounted for only seven percent of U.S. battery electric vehicle sales.

 

There is no indication Battery Day has been canceled or that there is an issue other than deciding how and when to make their full announcement. The event has already been postponed over 45 days, with no timeline expectations set. After the initial postponement, Musk announced, as mentioned earlier, a possible virtual event rather than live.  Social distancing still prevents the typical Telsa unveiling.  When the day finally happens, a rumor is that the electric storage design will be a leap forward in battery storage with many benefits for consumers. One benefit could be a reduced price. Tesla fans, bloggers, vloggers, and aficionados are expecting industry-changing news from the automotive giant.

 

 

Suggested Reading:

Cobalt and Rare Earth Metals from the Ocean Floor Eyed to Meet Growing Battery Demand

Space Force Will Require Emerging Technologies

Cryptocurrency and the Howey Test:
Are They Securities?

 

Enjoy Premium Channelchek Content at No Cost

 

Sources:

Tesla’s secret batteries aim to rework the math for electric cars and the grid

Musk Tweet April 13

Musk Cobalt Tweet

Statista

Tesla’s New Lithium-Ion Patent

 

Ely Gold Royalties (ELYGF) – Laying a Foundation for Growth

Tuesday, June 16, 2020

Ely Gold Royalties (ELYGF)(ELY:CA)

Laying a Foundation for Growth

As of April 24, 2020, Noble Capital Markets research on Ely Gold Royalties is published under ticker symbols (ELYGF and ELY:CA). The price target is in USD and based on ticker symbol ELYGF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Ely Gold Royalties Inc is an emerging royalty company with producing and development assets focused in Nevada and the Western US. It offers shareholders a low-risk leverage to the current price of gold and low-cost access to long-term gold royalties.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    White Rock Gold Project optioned to Provenance Gold.  Ely Gold Royalties entered into an option/sale agreement with Provenance Gold, Inc. for 30 unpatented lode mineral claims on the White Rock Gold Project located in Elko, Nevada. The option payments amount to US$250,000 over four years. Upon sale, Ely Gold will retain a 2.0% net smelter returns royalty which includes a $25,000 annual advance minimum royalty payment. In May, Ely entered into a similar option/sale agreement with Great Western Mining for claims on the Olympic Gold Project also in Nevada which underscores the value of the company’s available for sale portfolio.

    Expanding its gold royalty portfolio. In 2020, the company has announced the purchase of 8 producing or near-term producing royalties and option/sale agreements on several properties, including Olympic and White Rock. We believe potential exists for the company to announce additional…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Cocrystal Pharma Inc. (COCP) – Cocrystaling to combat viral diseases, Initiating Coverage

Tuesday, June 16, 2020

Cocrystal Pharma Inc. (COCP)

Cocrystaling to combat viral diseases, Initiating Coverage

Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Initiation of Coverage. We are initiating coverage on Cocrystal Pharma (COCP).. In our view, Cocrystal remains under the Street’s radar with its pipeline. Its versatile technology platform enables growth in new directions. As we look forward, we believe that three ongoing preclinical programs (influenza, coronavirus, and norovirus) may provide dynamic catalysts for the near/medium term. In addition, one IND filing (influenza program), expected in Q4 2020, provides fundamental depth to future value.

    The platform is foremost.  Cocrystal uses a proprietary platform to identify drug candidates to treat viral diseases. The anti-viral therapy segment is expected to reach…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Townsquare Media (TSQ) – Digital Shines, But Can The Stock Reflect It?

Tuesday, June 16, 2020

Townsquare Media Inc (TSQ)

Digital Shines, But Can The Stock Reflect It?

Townsquare Media Inc is an entertainment and media company offering digital marketing solutions in the United States and Canada. It owns and operates radio stations, social media properties focusing the small and mid-cap companies. Services offered to the clients include live events, local advertising, digital advertising, e-commerce offerings, few others. The segments through which the company operates its businesses are classified into Local marketing solutions and Entertainment segments. Revenues are generated from commercials through broadcasts and sale of internet based advertisements.

Michael Kupinski, DOR, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Q1 results were below estimates, but that was expected.  The Q1 miss was not a surprise given the Covid mitigation efforts. Revenues were $93.4 million, just slightly below low end of guidance, and cash flow, (adj. EBITDA) was $15.5 million versus our $19.4 million estimate. The company’s digital, Townsquare Interactive business grew revenues 16.3% and registered 850 new users, which now totals 19,850. Total digital revenues accounted for 40% of total company Q1 revenues.

    Interactive continues to grow.   Surprisingly, management indicated that Townsquare Interactive is on pace to add another 850 subscribers…




    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Cocrystaling to combat viral diseases, Initiating Coverage

Tuesday, June 16, 2020

Cocrystal Pharma Inc. (COCP)

Cocrystaling to combat viral diseases, Initiating Coverage

Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Initiation of Coverage. We are initiating coverage on Cocrystal Pharma (COCP).. In our view, Cocrystal remains under the Street’s radar with its pipeline. Its versatile technology platform enables growth in new directions. As we look forward, we believe that three ongoing preclinical programs (influenza, coronavirus, and norovirus) may provide dynamic catalysts for the near/medium term. In addition, one IND filing (influenza program), expected in Q4 2020, provides fundamental depth to future value.

    The platform is foremost.  Cocrystal uses a proprietary platform to identify drug candidates to treat viral diseases. The anti-viral therapy segment is expected to reach…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Onconova Therapeutics (ONTX) – INSPIRE Study Patients’ Genomic Profile at the Baseline

Monday, June 15, 2020

Onconova Therapeutics Inc. (ONTX)

INSPIRE Study Patients’ Genomic Profile at the Baseline

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Genomic data is presented at EHA. Onconova’s main focus is the pivotal INSPIRE study, assessing rigosertib in the 2nd-line high-risk myelodysplastic syndrome (HR-MDS) patients. The company presented genomic data at the baseline from 190 patients enrolled in this study.

    Future genomic data will be meaningful for the rigosertib clinical response. The baseline patient mutational profile showed that RAS pathway mutations were observed more commonly in patients that progressed on hypomethylating agents (HMA) therapy versus patients that failed HMA therapy. These results set the mutational profile for the patients prior to study treatment. The mutational analysis after the treatment will provide….




    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

INSPIRE Study Patients’ Genomic Profile at the Baseline

Monday, June 15, 2020

Onconova Therapeutics Inc. (ONTX)

INSPIRE Study Patients’ Genomic Profile at the Baseline

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Genomic data is presented at EHA. Onconova’s main focus is the pivotal INSPIRE study, assessing rigosertib in the 2nd-line high-risk myelodysplastic syndrome (HR-MDS) patients. The company presented genomic data at the baseline from 190 patients enrolled in this study.

    Future genomic data will be meaningful for the rigosertib clinical response. The baseline patient mutational profile showed that RAS pathway mutations were observed more commonly in patients that progressed on hypomethylating agents (HMA) therapy versus patients that failed HMA therapy. These results set the mutational profile for the patients prior to study treatment. The mutational analysis after the treatment will provide….




    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

The Limits of Government Economic Tinkering

Yield Curve Control, Stock Prices, and Trust

During late Summer, 1971, a repeat episode of Bonanza was pre-empted to air a special economic address from President Nixon. At the time, there was no economic emergency. The unemployment rate was 6%, which economists then considered “full employment,” and inflation was increasing but measured 4.4%. That day, Nixon discussed building what he called, “A New Prosperity.” He announced, “I am today ordering a freeze on all prices and wages throughout the United States.” As some historians tell the story, Nixon was focused on reelection in 1972 and saw the U.S. trade imbalance was increasing, this sent U.S. Dollars overseas to import goods. The imbalance left $45.7 billion of U.S. currency in the hands of foreign countries. At the time, the U.S. only held $14.5 billion in gold at $35 per ounce; this was one-third the needed reserves to cover the potential demand for international exchange of dollars to gold. Inflation was trending upward as a result of the excess unbacked dollars. The Fed acted by raising interest rates to help quell inflationary pressure and stabilize the dollar. The trend wasn’t improving.

The plan for a new prosperity immediately froze prices and wages for 90 days while creating a Pay Board and Price Commission to oversee wage and price increases as they were submitted for approval. A 10% surcharge was set on all imports to encourage purchasing U.S. made goods, and convertibility of U.S. Dollars to gold by foreign governments was suspended.

The plan was popular among voters and received favorable press. When the financial markets opened the next day, the Dow had its largest daily gain ever. Nixon was re-elected the following year. Shortly after, the country experienced a prolonged recession coupled with inflation (stagflation). The non-market price controls created significant shortages. There are examples of ranchers not shipping cattle to the market and farmers drowning chickens. The “prosperity” plan created an environment that wasn’t economically feasible for many businesses. By trying to create what many believed would be an economic ideal, the free market system had been stifled. Tinkering with the system wound up hurting the country. George Schulz, was Budget Director at the time, in 1973 he told Nixon, at least the debacle had convinced everyone, “that wage-price controls are not the answer.” Schulz was right; a decade later, Americans were still living with excessive inflation and high unemployment. Americans and investors are often in a more secure position when the playing field is left alone, when natural supply and demand mechanisms are trusted, and government tinkering in the economy and markets is kept to a minimum.

Yield Curve Control

After the Federal Open Market Committee’s (FOMC) two-day meeting ended on June 11th, Chairman Powell gave an update at a press conference. It began like this: “Good afternoon, everyone, and thanks for joining us. Our country continues to face a difficult and challenging time, as the pandemic is causing tremendous hardship here in the United States and around the world. People have lost loved ones. Many millions have lost their jobs. There is great uncertainty about the future. At the Federal Reserve, we are strongly committed to using our tools to do whatever we can, and for as long as it takes, to provide some relief and stability, to ensure that the recovery will be as strong as possible, and to limit lasting damage to the economy.” He then spoke of the rise in employment, rebound in car sales and retail, low inflation, and continued weakness in sectors of the economy most impacted by the pandemic. He reminded that the Fed’s mandate is to promote maximum employment and stable prices for the American people, along with the responsibility to promote a stable financial system.

Early in his talk, Powell made sure the press and viewers understood that the Fed has lending powers, not spending powers. He reminded them that fiscal policies such as the CARES Act are enacted by legislation to place collective resources in the hands of those they deem in need. The Fed’s powers only allow lending to solvent entities. He then reminded the audience what they probably already knew — the economy is weak, and with rates at or near zero, the Fed is powerless to use its more traditional tools to implement its mandate. But, within its ability to lend to solvent entities, there are other significant methods to impact economic activity.

Powell discussed using a possible monetary approach that was brought up at the May 8th meeting. The tool the Fed hasn’t used, with the overnight rate target at zero, is bringing down the shorter end of the yield curve. The Fed believes it has the ability to lower longer-term rates using what is called yield curve control (YCC).

If YCC is implemented, it could work like this. The Fed commits to buying whatever quantity of bonds the market supplies at its target yield (presumably below market yield, above market price). Quickly, bond markets will understand the central bank’s power; the target yield then becomes the market level. YCC is effectively price control of bonds with longer maturities than fed funds. The Fed would not have a need to engage in any buying if the bonds began trading at their target levels. Transactions would be at the Fed desired level as no one is going to sell the bonds at a cheaper price unnecessarily.

There is some history to gauge success. The Australian central bank began using YCC in March, but the Bank of Japan (BOJ) has been targeting points on the yield curve since 2016. Four years ago, the BOJ committed to targeting yield on 10-year Japanese Government Bonds to around zero percent. Their goal is to ward off deflation. Their approach to maintain the yield is to have an ongoing offer out to purchase outstanding bonds of any quantity at a price equating to their target yield. During periods when investors were less willing to pay that price, the BOJ purchased more bonds to keep yields at the target.

Although the BOJ has been successful with their efforts, it’s difficult to isolate and measure their success using YCC. Yield Curve Control is just one piece of the BOJ effort. Their policy is also implementing quantitative easing, forward guidance, and negative interest rates. Their goal is also different, its primary focus has been avoiding deflation. The BOJ mix of monetary policy steps has maintained a yield of zero percent out to 10 years.

If the U.S. Federal Reserve Bank began a YCC program, it would further impede the market’s natural price discovery tools and set a course based on what they deem would have the most agreeable outcome. Also, like other unconventional policies, retaining trust and credibility is necessary for the market to work within “the plan.” If, for example, the Fed were to commit to a yield target over the next two years, and one of their mandates, such as inflation, was to begin to rise, the market would have to trust that the Fed would not abandon the policy term which was in place when market participants put on their position. If the Fed altered course, trust would fall apart. Distrust of the Fed would cause market mayhem. Powell’s term is up in 2022; the market would have to trust that his successor would also abide by any long-term commitments.

Stock Prices

Whether the government’s activities in the bond market, through the Fed, are directed to the stock market or not, they have a collateral impact on investor behavior. This impact is a problem and a benefit to savers and investors.

The reaction to the pandemic, designed to minimize stress on the medical system by containing large scale spreading, threw the economy into reverse. Although much was not understood, what we did know is that those who were older or with medical conditions were at most risk of being hurt or dying from the disease. To protect citizens, the Federal government set guidelines which were largely adopted by the states, this stalled the robust economic activity we had been experiencing. Many of the people we were most concerned with spreading the virus are retirees that live on a fixed income. Their income may come from interest payments on certificates of deposit, bonds, and even annuities. With zero or close to zero return now, this same demographic has the choice of either living off the invested principal or taking a chance in riskier alternatives such as the stock market. One large fund family sent an email out to all of its participants. The warning in the email let them know that keeping money in their money market fund could net negative returns. This encourages riskier alternatives and creates additional stock market investors that would not have been in the market otherwise, thus incrementally increasing demand.

Even before the June FOMC meeting, stocks that pay steady dividends were strong. These investments typically get a boost from the Fed lowering rates as investors such as those mentioned above look for yield and a regular income stream. Another category that can do well with specific low rate conditions is banks. They borrow short term and lend longer term. A steeper yield curve benefits earnings, while a flat curve will tend to reduce earnings. The initial impact on finance companies is usually positive as they find themselves financing loans on the books at lower short rates.

Take-Away

There’s NO Such Thing as A Free Lunch is the title of a book by economist Milton Friedman and a popular market axiom. Our economic system makes it improbable that the government can push on one lever expecting a positive result without introducing an unnatural factor to the markets that have a consequence in another area. In the case of wage and price controls in the 1970s, the impact was severe. What will happen next with current non-market adjustments remains to be felt. Market participants will collectively move to anticipate the impact of the government and the Fed interactions by adjusting their positions. This alters sector earnings, investors will then lean toward or away from different investments. An example of this that we’ve recently experienced is that a mere utterance from Washington of them implementing tariffs brings down stock prices in related sectors.

It’s essential as an investor or as someone entrusted with the investments of others to have a plan for different scenarios before they occur. Nimbleness along with foresight of possible scenarios, and preplanned actions to adjust positions when a scenario unfolds, are key to performance. Using tariffs again as an example, the stock of primarily domestic companies not doing business abroad outperformed (semiconductors, chemicals, plastics, motorcycles, furniture, appliances, and the U.S. produced solar panels). The promise by the Fed of zero overnight rates and perhaps a flatter yield curve could make winners of investors in real estate, growth companies, banks, and others.

When you’re in the middle of a game and the rules change, some will benefit, and some will fall short. Constantly changing rules is where we find ourselves as market players. Whether we approve of the new rules or not, it’s best to master them as quickly as possible.

The new and proposed rules have been announced. Don’t fight the Fed.

Paul Hoffman

Managing Editor

 

Suggested Reading:

The Fed’s Power and Impact are Again
Tested

Fed’s Bond Purchases Will Impact
Equity Investors

Small-cap vs Large-cap Investing


Enjoy Premium Channelchek Content at No Cost


Sources:

Federal Reserve FOMC Statement June 2020

“Fed Listens” in Richmond: How Does Monetary Policy Affect Your Community?

The Fed Just Issued a Dire Warning for the Stock Market

The Federal Reserve Tries to Tame the Yield Curve

What is Yield Curve Control?

TIAA Says Negative Yields Could Soon be a Possibility in Money-Market Products

A New Investigation of the Impact of Wage and Price Controls

Transcript of Chair Powell Press Conference

 

Highlights from the Annual Shareholder Meeting

Friday, June 12, 2020

Aurania Resources (AUIAF)(ARU:CA)

Highlights from the Annual Shareholder Meeting

As of April 24, 2020, Noble Capital Markets research on Aurania Resources is published under ticker symbols (AUIAF and ARU:CA). The price target is in USD and based on ticker symbol AUIAF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Aurania Resources Ltd. is a Canada-based junior mining exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper. Its flagship asset, The Lost Cities-Cutucu Project, is in southeastern Ecuador in the Province of Morona-Santiago. The company also has several minor projects in Switzerland.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Aurania hosts Annual Shareholder Meeting. The company hosted a conference call and webcast on June 10. Management elaborated on its immediate plans to resume fieldwork at the Yawi gold and silver target, the Tsenken copper targets and its decision to apply for concessions in Peru. Commentary regarding recent LiDar imagery that revealed a network of roads that appeared to be converging toward an area where the historic gold mining center of Logrono de los Caballeros is thought to be located was of interest. This finding, along with another ancient road segment discovered in late 2019, could yield more clues to the location of two historic gold mining centers believed to be within the Lost Cities project area.

    Returning to the field.  Personnel have returned to the office in Macas, the capital of the Morona Santiago province of Ecuador, and teams are expected to return to the field this weekend. The company expects to deploy up to…




    Click to get the full report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Aurania Resources (AUIAF)(ARU:CA) – Highlights from the Annual Shareholder Meeting

Friday, June 12, 2020

Aurania Resources (AUIAF)(ARU:CA)

Highlights from the Annual Shareholder Meeting

As of April 24, 2020, Noble Capital Markets research on Aurania Resources is published under ticker symbols (AUIAF and ARU:CA). The price target is in USD and based on ticker symbol AUIAF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Aurania Resources Ltd. is a Canada-based junior mining exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper. Its flagship asset, The Lost Cities-Cutucu Project, is in southeastern Ecuador in the Province of Morona-Santiago. The company also has several minor projects in Switzerland.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Aurania hosts Annual Shareholder Meeting. The company hosted a conference call and webcast on June 10. Management elaborated on its immediate plans to resume fieldwork at the Yawi gold and silver target, the Tsenken copper targets and its decision to apply for concessions in Peru. Commentary regarding recent LiDar imagery that revealed a network of roads that appeared to be converging toward an area where the historic gold mining center of Logrono de los Caballeros is thought to be located was of interest. This finding, along with another ancient road segment discovered in late 2019, could yield more clues to the location of two historic gold mining centers believed to be within the Lost Cities project area.

    Returning to the field.  Personnel have returned to the office in Macas, the capital of the Morona Santiago province of Ecuador, and teams are expected to return to the field this weekend. The company expects to deploy up to…




    Click to get the full report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Gold is the New Green

Gold May Become Investors’ Favorite for Several Years

Gold investments are having a great week by any standard and a much better week than equities. The safe haven precious metal could maintain this strength for as long as the Federal Reserve Bank is intent on holding rates at zero. The Fed’s intentions were made public on Wednesday as Chairman Powell, said he expects the Fed to hold rates to near zero through 2022.

The Fed’s Outlook

Although not at their recent highs, gold futures, gold mining stocks, and physical gold traded higher after the announcement with strong follow-through Thursday as equity markets tumbled. Powell also presented the board’s forecast, which was disappointing for those expecting a sharp economic comeback. They foresee unemployment improving to only 9.3%, economic activity receding by 6.5% through 2020, and then GDP growing by 5% in 2021. The projections don’t have the U.S. at the same economic pace until sometime in 2022 when the Fed’s forecast is for an additional 3.5% increase. Through 2022 The Fed expects to keep rates near zero with no visible end to their buying Treasuries and other securities.

The Fed’s stated resolve, along with disruptions and concerns of global events, heightened additional interest in gold investments. During a phone interview with Bloomberg, Matt Weller, global head of market research at Gain Capital Group, LLC  said, “You almost couldn’t come up with a better script for a strong fundamental environment for gold than what we saw from the Fed yesterday.” The quote continues, “It’s really an environment of rampant monetary stimulus, and historically that’s exactly the type of environment in which gold has thrived.” Low yields on safe harbor securities such as U.S. Treasuries eliminate the lack of passive return that has caused bond purchasers to not prefer gold. Meanwhile, the stimulus could effectively reduce the value of the US Dollar while creating an inflationary environment. All of these together could be the perfect storm for gold to continue to outperform.

 Note: Gold futures (Aug ’20), mining stocks (Sprott Miners ETF as a proxy), and physical gold (Sprott Physical Gold Trust) on the chart above indicates the three are off their highs of April and May but now trending upward in synch.

During mid-March of this year, there had been a disconnect between mining stocks, physical gold ETF’s, and gold futures. Channelchek discussed the reasons in an article which then presented silver as an alternative for safe-haven investors. The recent resumption of air travel and reopening of mines that had been affected by lockdowns have caused the three popular forms of gold investments to trade at their more historical variances. The current one-year returns of the three are, as of June 11, 2020, 35% gold futures, 23% gold miners, and 22% physical gold.

Additional Strength

Precious metals still generate additional interest each time cases, and large pockets of novel coronavirus make the news. This creates additional strength in gold. The unknown and the possibility of a second wave of cases in the U.S. bring buyers in. Small surges of new infections in states including Texas, Florida, and California have raised concern among health experts even as the nation’s overall case count has experienced its smallest increase since March.

Dominic Schnider, head of commodities and Asia Pacific currencies at UBS Group AG, told Bloomberg Television, “The conditions are here for gold still going to $1,800.” He reminded the audience that low rates and the possibility for negative real rates (interest rates less inflation) would improve gold’s attractiveness.

Take-Away

Gold is in a position to test its high of the year and perhaps go much further. The conditions now would seem ideal, with the only caution being, “why aren’t they higher already?” The answer may be, despite unprecedented economic issues, optimists have controlled the markets. In a year where equity markets reached new highs against any sense of reason and companies have rallied double-digits after declaring bankruptcy, another possibility may very well be that there were too many distractions and other opportunities. Economic optimism appears to be fading again. The stage is set for gold investments to continue to shine; time will tell if they do.

 

Virtually attend live: Channelchek Virtual Road Show Series presents ELY GOLD Wednesday, June 17th @ 1 pm EST (participants limited to 100).

 

Suggested Reading:

Where New
Savings and Investment is Coming From

Why Gold
Could Retain Its Luster

 

Enjoy Premium Channelchek Content at No Cost

 

Sources:

Gold Set for Biggest Gain in a Month

Jay
Powell Lets it Loose

Gold Set for Biggest Gain in a Month on Fed View, Virus Concerns

C1 Technology to Produce High-Level and Cost-Effective Biologics to Combat Coronavirus

Wednesday, June 10, 2020

Dyadic International Inc. (DYAI)

C1 Technology to Produce High-Level and Cost-Effective Biologics to Combat Coronavirus

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the industrially proven hyper productive engineered fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Coronavirus remains to be a major threat to human lives and the economy. The coronavirus pandemic is still a major threat to human lives. The number of confirmed cases reached over 7.1 million and the death attributed to Covid-19 now exceeds 400,000 globally, according to the World Health Organization.

    Manufacturing massive amounts of vaccines and antibodies may be an emerging hurdle. The regulatory agencies, biotechnology, and pharmaceuticals world combine efforts to combat coronavirus. The federal government plans to conduct Phase 3 clinical trials to assess vaccine candidates this summer. Many efforts are focused on rapid progress to bring an effective vaccination and treatment method on the market. However, producing massive amounts…



    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.